1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Hubei Jumpcan Pharmaceutical Co., Ltd.

Hubei Jumpcan Pharmaceutical Co., Ltd.

600566.SS
Hubei Jumpcan Pharmaceutical Co., Ltd.CN flagShanghai Stock Exchange
24.35
CNY
+0.56
- -
22.44BMarket Cap
Hubei Jumpcan Pharmaceutical Co., Ltd.
600566.SS
(Shanghai Stock Exchange)

Recent

price

24.35

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.71
1.74
3.15
4.01
3.85
4.83
5.86
6.96
8.88
8.51
7.39
8.61
10.11
10.53
8.74
6.75
7.34
Revenue per Share
0.06
0.06
0.39
0.66
0.67
0.88
1.17
1.51
2.08
1.99
1.53
1.94
2.44
3.08
2.76
1.93
2.09
Basic EPS, GAAP
-0.18
-0.44
-0.01
0.03
0.41
0.32
0.74
0.55
1.28
1.96
1.62
1.86
2.67
3.45
2.18
1.2
-0.12
Free Cash Flow per Basic Share
0.09
0.09
0.54
0.03
0.05
0.4
0.69
0.73
1
1.23
1.21
0.46
0.68
0.9
1.33
2.09
2.11
Dividend per Share
1.7
1.75
1.04
1.2
1.57
1.95
2.4
3.15
4.26
5
5.25
6.44
8.19
10.15
11.6
11.39
10.29
Book Value per Share
3.57
3.63
1.18
1.67
2.78
2.99
4.13
4.95
6.15
6.87
8.76
9.8
12.21
14.06
15.53
15.34
14.24
Tangible Book Value per Share
138
138
609
610
775
780
798
810
811
816
835
886
890
916
917
921
917
Basic Weighted Avg Shares
237
240
1,920
2,448
2,986
3,768
4,678
5,642
7,208
6,940
6,165
7,631
8,996
9,655
8,017
6,219
6,731
Sales/Revenue/Turnover
9.19
7.91
13.05
17.73
18.74
19.93
22.48
24.28
26.23
26.13
22.73
22.15
25.68
30.05
30.18
30.19
28.47
Operating Margin (%)
21
23
47
61
81
109
117
152
176
232
281
294
309
303
308
311
- -
Depreciation Expense
8
8
238
403
519
687
934
1,223
1,688
1,623
1,277
1,719
2,171
2,823
2,532
1,778
1,918
Net Income, GAAP
2.85
4.15
17.2
13.37
14.1
14.56
14.12
14.74
14.62
14.27
13.91
11.96
13.41
14.26
14.83
17.76
15
Effective Tax Rate (%)
3.57
3.29
12.38
16.45
17.39
18.22
19.97
21.68
23.42
23.39
20.72
22.53
24.13
29.24
31.58
28.59
28.49
Profit Margin (%)
15
89
-95
115
943
878
1,527
2,222
2,691
3,072
4,607
5,322
7,749
9,644
11,164
11,304
10,090
Working Capital
- -
95
110
- -
- -
- -
- -
698
553
576
605
1
- -
1
1
1
1
LT Debt
520
527
750
1,152
2,294
2,713
3,688
4,402
5,480
6,104
7,763
9,131
11,352
13,369
14,726
14,633
13,532
Total Equity
2.88
2.34
21.39
29.59
24.08
24.23
28.11
26.44
28.94
24.43
15.98
16.38
18.47
18.82
13.68
9.88
11.21
Return on Invested Capital (%)
4.66
3.75
33.02
42.1
42.05
45.25
53.18
47.22
47.32
38.09
27.07
30.89
31.25
31.36
23.37
15.72
18.58
Return on Capital (%)
3.92
3.32
54.35
59
53.35
50.23
54.35
54.72
56.2
43.11
30.19
34.07
33.41
34.03
25.4
16.83
20.31
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
788
628
533
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
922
922
922
Market Capitalization
26,718
25,503
24,154

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
14,702
14,637
13,038
Cash, Cash Equivalents & STI
11,830
12,583
10,925
Accounts Receivable, Net
2,173
1,393
1,610
Inventories
569
457
339
Total Current Liabilities
3,538
2,967
2,949
Payables & Accruals
- -
- -
- -
ST Debt
788
628
533
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.76%
13.84%
-0.64%
Free Cash Flow
30.24%
3.51%
-44.94%
Net Income, GAAP
13.07%
10.16%
-29.77%
Sales/Revenue/Turnover
6.72%
1.92%
-22.43%
Total Cash Common Dividend
27.4%
26.15%
58.38%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,403
1,632
1,771
2,212
8,017
2025
1,525
1,223
2,287
- -
6,219
2026
1,207
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.92
- -
- -
- -
2.76
2025
0.48
- -
- -
- -
1.93
2026
0.44
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
1.33
2025
- -
- -
- -
- -
2.09
2026
0.01
- -
- -
- -
- -
Similar Companies
Quantum BioPharma Ltd. (QNTM)
Captiva Verde Wellness Corp. (PWR.CN)
Copland Road Capital Corporation (CRCC.CN)
Benchmark Holdings plc (BMK.L)
Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ)
China Shineway Pharmaceutical Group Limited (CSWYY)
Business
Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SS) is a China-based pharmaceutical company engaged in the research, development, production, and sale of pharmaceutical products, including chemical drugs, biological preparations, and traditional Chinese medicines. The company offers a range of core products such as cardiovascular medications, anti-infective drugs, nervous system therapeutics, and digestive system treatments; its key brands include proprietary formulations like Jumpcan-branded tablets and injectables targeted at hospitals, clinics, and retail pharmacies across China. Founded in 1993 and headquartered in Shiyan, Hubei Province, Jumpcan operates primarily in the domestic market with manufacturing facilities concentrated in central China, serving major customer segments in the healthcare sector including public hospitals and pharmaceutical wholesalers. In recent developments, the company has focused on expanding its production capacity through strategic investments in new facilities and technology upgrades, with no major acquisitions, partnerships, or name changes reported in the last 1-2 years as of late 2025. Jumpcan continues to emphasize R&D in innovative generics and biosimilars to align with China's national healthcare reforms, including participation in volume-based procurement programs that have shaped its competitive positioning. The firm maintains a straightforward corporate structure without notable subsidiaries or parent affiliations, concentrating operations within the mainland Chinese pharmaceutical industry.